Substance-abuse treatment and mortality

Journal of Public Economics

Volumn 122, Issue , 2015, Pages 13-30

  Swensen, Isaac D ^a  

^a MONTANA STATE UNIVERSITY   (United States)

Author keywords

Drug abuse; Health economics; Mortality; Public health; Substance abuse treatment

Indexed keywords

EID: 84920733583     PISSN: 00472727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpubeco.2014.12.008     Document Type: Article

References (58)

1. Aldy J.E., Viscusi W.K. Adjusting the value of a statistical life for age and cohort effects. Rev. Econ. Stat. 2008, 90(3):573-581.
2. Altonji J., Elder T., Taber C. Selection on Observed and Unobserved Variables: Assessing the Effectiveness of Catholic Schools. J. Polit. Econ. 2005, 113(1):151-184.
3. Amato L., Davoli M., Perucci C.A., Ferri M., Faggiano F., Mattick R.P. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J. Subst. Abus. Treat. 2005, 28(4):321-329.
4. Anderson D.M. Does information matter? The effect of the Meth Project on meth use among youths. J. Health Econ. 2010, 29(5):732-742.
5. Arndt S., Clayton R., Schultz S.K. Trends in substance abuse treatment 1998-2008: increasing older adult first-time admissions for illicit drugs. Am. J. Geriatr. Psychiatr. 2012, 19(8):704-711.
6. Arthur W.B. The economics of risks to life. Am. Econ. Rev. 1981, 71(1):54-64.
7. Brewer D.D., Catalano R.F., Haggerty K., Gainey R.R., Fleming C.B. A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction 1998, 93(1):73-92.
8. Brownstein H.H., Baxi H.R.S., Goldstein P.J., Ryan P.J. The relationship of drugs, drug trafficking, and drug traffickers to homicide. J. Crime Justice 1992, 15(1):25-44.
9. Buck J.A. The looming expansion and transformation of public substance abuse treatment under the Affordable Care Act. Health Aff. 2011, 30(8):1402-1410.
10. Cartwright W.S. Cost-benefit analysis of drug treatment services: review of the literature. J. Ment. Health Policy Econ. 2000, 3(1):11-26.
11. Caulkins J., Reuter P. What price data tell us about drug markets. J. Drug Issues 1998, 28:593-612.
12. Cohen A., Freeborn B., McManus B. Competition and crowding-out in the market for outpatient substance abuse treatment. Int. Econ. Rev. 2013, 54(1):159-184.
13. Cunningham J.K., Liu L.M. Impacts of federal ephedrine and pseudoephedrine regulations on methamphetamine-related hospital admissions. Addiction 2003, 98(9):1229-1237.
14. Cunningham J.K., Liu L.M. Impacts of federal precursor chemical regulations on methamphetamine arrests. Addiction 2005, 100(4):479-488.
15. Dave D., Mukerjee S. Mental health parity legislation, cost-sharing and substance-abuse treatment admissions. Health Econ. 2011, 20(2):161-183.
16. DiNardo J. Law enforcement, the price of cocaine and cocaine use. Math. Comput. Model. 1993, 17(2):53-64.
17. Dobkin C., Nicosia N. The war on drugs: methamphetamine, public health, and crime. Am. Econ. Rev. 2009, 99(1):324.
18. Dobkin C., Puller S.L. The effects of government transfers on monthly cycles in drug abuse, hospitalization and mortality. J. Public Econ. 2007, 91(11-12):2137-2157.
19. Dobkin, C., Nicosia, N., Weinberg, M., 2013. "How Effective are Enforcement Efforts Targeting Illegal Drugs?" Unpublished Manuscript.
20. Evans W.N., Moore T.J. The short-term mortality consequences of income receipt. J. Public Econ. 2011, 95:1410-1424.
21. Green C.A., Polen M.R., Dickinson D.M., Lynch F.L., Bennett M.D. Gender differences in predictors of initiation, retention, and completion in an HMO-based substance abuse treatment program. J. Subst. Abus. Treat. 2002, 23(4):285-295.
22. Griffith J.D., Rowan-Szal G.A., Roark R.R., Simpson D.D. Contingency management in outpatient methadone treatment: a meta-analysis. Drug Alcohol Depend. 2000, 58(1-2):55-66.
23. Honore B.E., Lleras-Muney A. Bounds in competing risks models and the war on cancer. Econometrica 2006, 74(6):1675-1698.
24. Horgan C.M., Merrick E.L. Financing of substance abuse treatment services. Alcoholism 2001, 229-252. Springer.
25. Hser Y.I., Teruya C., Brown A.H., Huang D., Evans E., Anglin M.D. Impact of California's proposition 36 on the drug treatment system: treatment capacity and displacement. Am. J. Public Health 2007, 97(1):104.
26. Hubbard R.L., Marsden M.E., Cavanaugh E., Rachal J.V., Ginzburg H.M. Role of drug-abuse treatment in limiting the spread of AIDS. Rev. Infect. Dis. 1988, 10(2):377-384.
27. Khalsa J.H., Treisman G., McCance-Katz E., Tedaldi E. Medical consequences of drug abuse and co-occurring infections: research at the National Institute on Drug Abuse. Subst. Abus. 2008, 29(3):5-16.
28. Kochanek K.D., Murphy S.L., Xu J., Minio A., Kung H. Deaths: final data for 2009. Natl. Vital Stat. Rep. 2011, 60(3).
29. Kuziemko I., Levitt S.D. An empirical analysis of imprisoning drug offenders. J. Public Econ. 2004, 88(9):2043-2066.
30. Lu M., McGuire T.G. The productivity of outpatient treatment for substance abuse. J. Hum. Resour. 2002, 309-335.
31. McCollister K.E., French M.T. The relative contribution of outcome domains in the total economic benefit of addiction interventions: a review of first findings. Addiction 2003, 98(12):1647-1659.
32. Menninger J.A. Assessment and treatment of alcoholism and substance-related disorders in the elderly. Bull. Menn. Clin. 2002, 66(2):166-183.
33. Miron J.A. Violence and the US prohibitions of drugs and alcohol. Am. Law Econ. Rev. 1999, 1(1):78-114.
34. Moscicki E.K. Epidemiology of suicidal behavior. Suicide Life Threat. Behav. 1995, 25(1):22-35.
35. National Drug Intelligence Center (NDIC) The Economic Impact of Illicit Drug Use on American Society 2011, United States Department of Justice, Washington DC.
36. Office of National Drug Control Policy FY 2005 Budget Summary 2005, Executive Office of the President, Washington, DC.
37. Olmstead T., White W.D., Sindelar J. The impact of managed care on substance abuse treatment services. Health Serv. Res. 2004, 39(2):319-344.
38. Paulozzi L.J., Annest J.L. US data show sharply rising drug-induced death rates. Inj. Prev. 2007, 13(2):130-132.
39. Prendergast M.L., Podus D., Chang E., Urada D. The effectiveness of drug abuse treatment: a meta-analysis of comparison group studies. Drug Alcohol Depend. 2002, 67(1):53-72.
40. Reif S., George P., Braude L., Dougherty R.H., Daniels A.S., Ghose S.S., Delphin-Rittmon M.E. Residential treatment for individuals with substance use disorders: assessing the evidence. Psychiatr. Serv. 2014, 65:301-312.
41. Ruhm C.J. Healthy living in hard times. J. Health Econ. 2005, 24(2):341-363.
42. Ruhm C.J. Macroeconomic conditions, health and government policy. Making Americans Healthier: Social and Economic Policy as Health Policy: Rethinking Americas Approach to Improving Health 2008, 173-200. Russel Sage Foundation, New York.
43. Rydell C.P., Everingham S.S. Controlling Cocaine: Supply Versus Demand Programs 1994, vol. 331. Rand Corp.
44. Sacerdote P. Opioids and the immune system. Palliat. Med. 2006, 20(8 suppl):9-15.
45. Saffer H., Chaloupka F. The demand for illicit drugs. Econ. Inq. 1999, 37(3):401-411.
46. Saffer H., Chaloupka F.J., Dave D. State drug control spending and illicit drug participation. Contemp. Econ. Policy 2007, 19(2):150-161.
47. Shepard D.S., Beaston-Blaakman A., Horgan C. The ADSS Cost Study: Costs of Substance Abuse Treatment in the Specialty Sector. Analytic Series: A-20 2003, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Rockville, MD, (DHHS Publication No. SMA 03-3762).
48. Solon G., Haider S.J., Wooldridge J. What are we weighting for?. NBER Working Paper No. 18859. 2013.
49. Stein Michael D. Medical consequences of substance abuse. Psychiatric Clinics of North America 1999, 22(2):351-370.
50. Stevens A.H., Miller D.L., Page M.E., Filipski M. The best of times, the worst of times: understanding pro-cyclical mortality. NBER Working Paper No. 17657 2011.
51. Stinchcomb J.B. Drug courts: conceptual foundation, empirical findings, and policy implications. Drugs Educ. Prev. Policy 2010, 17(2):148-167.
52. Substance Abuse and Mental Health Services Administration (SAMHSA), Office of Applied Studies National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on Substance Abuse Treatment Facilities. DASIS Series: S-44, DHHS Publication No. (SMA) 08-4348, Rockville, MD 2008.
53. Substance Abuse and Mental Health Services Administration (SAMHSA), Office of Applied Studies Treatment Episode Data Set (TEDS). Highlights - 2007. National Admissions to Substance Abuse Treatment Services. DASIS Series: S-45, DHHS Publication No. (SMA) 08-4360, Rockville, MD 2009.
54. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality The N-SSATS Report: Acceptance of Private Health Insurance in Substance Abuse Treatment Facilities 2011, (January 6, 2011).
55. Substance abuse and mental health services administration, office of applied studies Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. Rockville, MD 2011.
56. Tempalski B., Friedman R., Keem M., Cooper H., Friedman S.R. NIMBY localism and national inequitable exclusion alliances: the case of Syringe Exchange Programs in the United States. Geoforum 2007, 38(6):1250-1263.
57. Viscusi W.K., Aldy J.E. The value of a statistical life: a critical review of market estimates throughout the world. J. Risk Uncertain. 2003, 27(1):5-76.
58. Warner M., Chen L.H., Makuc D.M., Anderson R.N., Minio A.M. Drug poisoning deaths in the United States, 1980-2008. NCHS Data Brief. 2011, 81. National Center for Health Statistics, Hyattsville, MD.